More Penthrox Licensing Agreements Expected
12 May 2015 ASX ANNOUNCEMENT More Penthrox Licensing Agreements Expected To facilitate distributing Penthrox internationally, Medical Developments International Limited (ASX: MVP) established a restricted confidential electronic data room in FY14 for prospective license partners.? The data room has attracted more than 30 companies and to date MVP has concluded Licensing & Distribution agreements for Penthrox […]
Read moreNear term planning for the globalisation of Penthrox
8 May 2015 ASX ANNOUNCEMENT Near term planning for the globalisation of Penthrox The approval of Penthrox for use in the United Kingdom, France, Belgium and Ireland validates our Regulatory Dossier and the clinical and safety data we have obtained for Penthrox.? It proves Penthrox is a ?world class? product which regulatory authorities around the […]
Read morePenthrox Regulatory Approval in UK and Europe
6 May 2015 ASX Announcement Penthrox successfully completes its Decentralised Regulatory Approval Procedure in Europe Medical Developments International Limited (ASX: MVP) is delighted to announce that the Medicine and Healthcare products Regulatory Agency (?MHRA?) has issued the Final Assessment Report with the support of France, Belgium and Ireland authorities noting all outstanding issues pursuant to […]
Read moreASX Announcement – Green Whistle: Positive ?Regulatory Approval? feedback from European Regulatory Authorities
Medical Developments International Limited (ASX:MVP) is delighted to announce that it has received positive feedback from the Medicine and Healthcare products Regulatory Agency (?MHRA?) to market and sell its inhaled analgesic product, ?Penthrox?? in the United Kingdom, and by extension to France, Belgium and Ireland via the Decentralised Procedure. The MHRA has also outlined the […]
Read moreASX Announcement – Green Whistle: Positive “Regulatory Approval” feedback from European Regulatory Authorities
Medical Developments International Limited (ASX:MVP) is delighted to announce that it has received positive feedback from the Medicine and Healthcare products Regulatory Agency (“MHRA”) to market and sell its inhaled analgesic product, ‘Penthrox®’ in the United Kingdom, and by extension to France, Belgium and Ireland via the Decentralised Procedure. The MHRA has also outlined the […]
Read moreASX Announcement – Major European deal for Penthrox
Medical Developments International (MVP) is delighted to announce it has entered into an exclusive Distribution, License and Supply Agreement with Galen Limited (Galen) to supply Penthrox in the United Kingdom and Ireland. The agreement has an initial term of 5 years and represents the first major milestone for MVP in terms of its European expansion […]
Read more